Startseite>>Signaling Pathways>> Tyrosine Kinase>> EGFR>>BIBX 1382

BIBX 1382 (Synonyms: Falnidamol;BIBX-1382;BIBX1382)

Katalog-Nr.GC10087

An EGFR inhibitor

Products are for research use only. Not for human use. We do not sell to patients.

BIBX 1382 Chemische Struktur

Cas No.: 196612-93-8

Größe Preis Lagerbestand Menge
5mg
70,00 $
Auf Lager
10mg
125,00 $
Auf Lager
50mg
430,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product Documents

Quality Control & SDS

View current batch:

Protocol

Animal experiment:

Animal administration[1]Five- to six-week-old athymic NMRI-nu/nu female mice (21-31 g) were inoculated s.c. with 1 × 106 (in 100 μl) A431, FaDu, or HN5 cells into the right flank of the animal. After 7 to 11 days, tumors reached a average volume of 40 to 130 mm3. The mice were randomized and treated daily p.o. with Falnidamol (BIBX 1382), BIBU1361, or vehicle control on the basis of individual weights. Tumors were measured three times a week with calipers, and tumor volumes were calculated by the formula π/6 × length × (width)2. Experimental compounds were prepared in 25% aqueous hydroxypropyl-β-cyclodextrin and administered by intragastral gavage. The administration volume was 10 ml/kg b.wt.

References:

[1]. Solca FF, et al. Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. J Pharmacol Exp Ther. 2004 Nov;311(2):502-9.

Background

BIBX1382 is a potent, selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase with IC50 value of 3 nM.[1]

BIBX1382 is an inhibitor of EGFR kinase for treatment of cancer. In a tyrosine kinase activity assay using cytoplasmic tyrosine kinase domains of EGFR, HER2, VEGFR2, HGFR, IGF1R, B-InsRK and c-src cloning and expressing in Sf9 insect cells, BIBX1382 selectively and potently inhibited EGFR kinase activity with an IC50 value of 3 nM. In the EGFR and pEGFR ELISA assay using EGFR highly expressed A431 cells (vuval squamous cell carcinoma), BIBX1382 inhibited EGFR phosphorylation at EC50 at 141 nM.[1] In A431, FaDu (hypopharyngeal squamous cell carcinoma) and HN5 (head and neck squamous cell carcinoma) xenograft nude mice models, oral administration of BIBX1382 at dose of 10 mg/kg daily showed strong antitumor activity in a dose-dependent manner after 2 weeks of treatment. Moreover, tumor regressions were obtained after 170 days’ long term oral administration of BIBX1382 at dose of 50 mg/kg daily in A431 xenograft nice model.[1]

References:
1. F. F. Solca, A. Baum, E. Langkopf, G. Dahmann, K. H. Heider, F. Himmelsbach and J. C. van Meel, J Pharmacol Exp Ther 2004, 311, 502-509.

Chemical Properties

Cas No. 196612-93-8 SDF
Überlieferungen Falnidamol;BIBX-1382;BIBX1382
Chemical Name N8-(3-chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine
Canonical SMILES CN1CCC(NC2=NC=C3C(C(NC4=CC(Cl)=C(F)C=C4)=NC=N3)=N2)CC1
Formula C18H19ClFN7 M.Wt 387.84
Löslichkeit DMF: 30 mg/ml,DMSO: 30 mg/ml,DMSO:PBS (pH 7.2) (1:3): 0.25 mg/ml Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 2.5784 mL 12.8919 mL 25.7838 mL
5 mM 0.5157 mL 2.5784 mL 5.1568 mL
10 mM 0.2578 mL 1.2892 mL 2.5784 mL
  • Molaritätsrechner

  • Verdünnung-Rechner

Gewicht
=
Konzentration
x
Inhalt
x
MW*
 
 
 
**Bei der Herstellung von Stammlösungen ist immer das chargenspezifische Molekulargewicht von

Berechnen

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Bewertungen

Review for BIBX 1382

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BIBX 1382

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.